title: [The relation between the perception of dyspnea and beta 2-agonists consumption in patients with mild-moderate asthma].
abstract: It is well documented that, in patients with asthma, there is a considerable variation in the severity of breathlessness for any particular degree of airflow obstruction. The factors underlying this variability are still to be explored. The consumption of beta 2-agonists and the perception of dyspnea were assessed in eighty asthmatic patients, with mild-moderate asthma, attending the asthma clinic. The perception of dyspnea was compared to sixty normal subjects. All patients received treatment with inhaled corticosteroid and beta 2-agonists as needed. Nine patients were excluded from the study, hence the data reported relates to 71 patients. In 55% of the patients the mean score of the perception of dyspnea during breathing against resistance was normal, it was low in 20 (28%) and high in the remaining 12 (17%). There was no correlation between the FEV1 and the perception of dyspnea. The mean +/- SEM beta 2-agonists consumption was 2.9 +/- 0.4 puffs/day (range 0-7.2). There was a statistically significant difference in beta 2-agonists consumption between the mid asthmatic and the moderate asthmatic groups (p < 0.01). In both groups the mean beta 2-agonists consumption was significantly higher in the high preception of dyspnea group than in the normal (p < 0.05) and the low (p < 0.01) perception of dyspnea groups. We conclude that about half of mild-moderate asthmatic patients have normal perception of dyspnea while the other half have either high or low perception of dyspnea. More obstructed patients have higher beta 2-agonists consumption. However, in every degree of severity there is a close relation between the perception of dyspnea and the beta 2-agonists consumption.
authors.affiliation: Department of Medicine, A Hillel-Yaffe Medical Center, Hadera, Israel.
authors.forename: Paltiel
authors.initials: P
authors.lastname: Weiner
authors.forename: Rasmi
authors.initials: R
authors.lastname: Magadle
authors.forename: Noa
authors.initials: N
authors.lastname: Berar-Yanay
authors.forename: Marinella
authors.initials: M
authors.lastname: Beckerman
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D004417:Dyspnea / Q000503:physiopathology* / Q000523:psychology; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D010465:Perception; D012044:Regression Analysis; D015656:Respiratory Mechanics
chemical_list: D000318:Adrenergic beta-Agonists